Understanding Post-translational Modifications to Circulating Histones Via Mass Spectrometry in Pregnant Women Developing Pre-eclampsia: A Retrospective Study
- Conditions
- Pregnancy RelatedPre-Eclampsia
- Interventions
- Diagnostic Test: Analysis of post-translational histone modifications via mass spectrometry
- Registration Number
- NCT05142410
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Brief Summary
This is a descriptive pilot study on a ready-constituted biobank (outside the Jardé Law). It is an ancillary study to the "GrossPath" cohort (RCB ID number: 2014-A01120-47).
Pregnancy generates an increased risk of thrombosis, and placenta-mediated diseases constitute a risk factor for cardiovascular pathologies responsible for significant maternal-fetal morbidity and mortality. Understanding and exploring the cellular and molecular mechanisms of dysfunctions of the vascular-placental interface could provide arguments to understand the systemic vascular risk, characterize it and finally detect it on the basis of new markers, thus opening the way for targeted preventive management to reinforce the general principles of precision medicine.
Netosis is a process of activation of neutrophils, which then generate filaments containing DNA, enzymes and extracellular histones. Netosis occurs in pregnancy and is increased in vascular-placental complications. It can be studied by measuring circulating histones, particularly the citrullinated histone H3. Levels of this modified histone H3, as well as those of two other modifications, have recently been shown to increase during pregnancy. These levels have also been shown to be even greater in pregnancy complications.
The aim of this study is to complete this mapping in order to obtain a precise signature for all post-translational histone modifications in normal pregnancies and pregnancies complicated by pre-eclampsia from the "GrossPath" cohort in order to propose new circulating biomarkers for placental vascular pathologies.
The post-translational histone modification profiles (mapping) of pregnant women with normal pregnancies will be compared with those developing pre-eclampsia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 28
- Not applicable as this study is on samples from a biobank. The inclusion criteria for the "GrossPath" cohort were:
- pregnant women followed at Nîmes University hospital for normal pregnancy or pregnancy with placental vascular pathology (pre-eclampsia and/or intra-uterine growth retardation).
- The patient must have given her free and informed consent and signed the consent form.
- The patient must be a member or beneficiary of a health insurance plan
- Only women are included
- Patients are at least 18 years old
- Not applicable as this is a study on samples from a biobank. The non-inclusion criteria of the "GrossPath" cohort were :
- twin pregnancies.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Plasma from women with normal pregnancies Analysis of post-translational histone modifications via mass spectrometry Plasma collected from women with normal pregnancies will be analyzed by mass spectrometry Plasma from women with placenta-mediated complications Analysis of post-translational histone modifications via mass spectrometry Plasma collected from women who developed preeclampsia during pregnancy will be analyzed by mass spectrometry
- Primary Outcome Measures
Name Time Method Presence of methylation in histone H2A in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of methylation in histone H2A and recorded as YES/NO.
Presence of methylation in histone H3 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of methylation in histone H3 and recorded as YES/NO.
Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of acetylation in histone H3 and recorded as YES/NO.
Presence of phosphorylation in histone H2B in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2B and recorded as YES/NO.
Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2B and recorded as YES/NO.
Presence of methylation in histone H3 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of methylation in histone H3 and recorded as YES/NO.
Presence of phosphorylation in histone H2A in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2A and recorded as YES/NO.
Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of citrullination in histone H2B and recorded as YES/NO.
Presence of methylation in histone H2B in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of methylation in histone H2B and recorded as YES/NO.
Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of acetylation in histone H2A and recorded as YES/NO.
Presence of methylation in histone H4 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of methylation in histone H4 and recorded as YES/NO.
Presence of acetylation in histone H2A in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of acetylation in histone H2A and recorded as YES/NO.
Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2A and recorded as YES/NO.
Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H4 and recorded as YES/NO.
Presence of ubiquitination in histone H2A in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2A and recorded as YES/NO.
Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2B and recorded as YES/NO.
Presence of ubiquitination in histone H4 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H4 and recorded as YES/NO.
Presence of citrullination in histone H3 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of citrullination in histone H3 and recorded as YES/NO.
Presence of methylation in histone H2A in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of methylation in histone H2A and recorded as YES/NO.
Presence of methylation in histone H2B in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of methylation in histone H2B and recorded as YES/NO.
Presence of methylation in histone H4 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of methylation in histone H4 and recorded as YES/NO.
Presence of acetylation in histone H4 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of acetylation in histone H4 and recorded as YES/NO.
Presence of phosphorylation in histone H3 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H3 and recorded as YES/NO.
Presence of ubiquitination in histone H2B in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2B and recorded as YES/NO.
Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H4 and recorded as YES/NO.
Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of citrullination in histone H2A and recorded as YES/NO.
Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of citrullination in histone H3 and recorded as YES/NO.
Presence of acetylation in histone H2B in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of acetylation in histone H2B and recorded as YES/NO.
Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of acetylation in histone H2B and recorded as YES/NO.
Presence of acetylation in histone H3 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of acetylation in histone H3 and recorded as YES/NO.
Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of acetylation in histone H4 and recorded as YES/NO.
Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2A and recorded as YES/NO.
Presence of ubiquitination in histone H3 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H3 and recorded as YES/NO.
Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H3 and recorded as YES/NO.
Presence of citrullination in histone H2B in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of citrullination in histone H2B and recorded as YES/NO.
Presence of citrullination in histone H4 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of citrullination in histone H4 and recorded as YES/NO.
Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of citrullination in histone H4 and recorded as YES/NO.
Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H3 and recorded as YES/NO.
Presence of phosphorylation in histone H4 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H4 and recorded as YES/NO.
Presence of citrullination in histone H2A in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry will be used to detect the presence or not of citrullination in histone H2A and recorded as YES/NO.
- Secondary Outcome Measures
Name Time Method Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of acetylation in histone H4 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of phosphorylation in histone H2B in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of phosphorylation in histone H4 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of ubiquitination in histone H3 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of citrullination in histone H2A in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Presence of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 of pregnancy Mass spectrometry, quantitative
Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of acetylation in histone H3 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of ubiquitination in histone H2A in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of citrullination in histone H3 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Presence of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of acetylation in histone H2B in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of methylation in histone H2A in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of methylation in histone H3 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of methylation in histone H4 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of acetylation in histone H2A in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of ubiquitination in histone H4 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of citrullination in histone H4 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Presence of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy After 34 weeks of pregnancy YES/NO
Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of methylation in histone H2B in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of phosphorylation in histone H3 in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of phosphorylation in histone H2A in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of ubiquitination in histone H2B in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of citrullination in histone H2B in pregnant women with normal pregnancies At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Presence of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 of pregnancy YES/NO
Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia At pregnancy term (max 41 weeks gestation) Mass spectrometry, quantitative
Presence of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies. 34 to 41 weeks of pregnancy The presence of methylation, acetylation, phosphorylation, ubiquitination and citrullination in each histone in women developing pre-eclampsia later on will be recorded as YES/NO.
Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies. 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy YES/NO
Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy YES/NO
Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy Before 34 weeks of pregnancy Mass spectrometry, quantitative
Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy 34 to 41 weeks of pregnancy Mass spectrometry, quantitative
Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies. Before 34 weeks of pregnancy The presence of methylation, acetylation, phosphorylation, ubiquitination and citrullination in each histone in women developing pre-eclampsia early on will be recorded as YES/NO.
Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies. Before 34 weeks of pregnancy Mass spectrometry, quantitative
Trial Locations
- Locations (1)
Nîmes University Hospital
🇫🇷Nîmes, Gard, France